CJC-1295 (senza dac)+ Ipamorelin

Product Overview

This 5 mg + 5 mg research blend pairs CJC-1295 without DAC (MOD GRF 1-29) with Ipamorelin to facilitate laboratory assessments of pulsatile GH axis modulation in controlled experimental setups.

Peptide Overview

From 2013 to 2025, scientific interest in short-acting GH-related peptides has grown substantially. The joint analysis of CJC-1295 without DAC and Ipamorelin empowers labs to probe receptor-specific responses, pituitary signaling patterns, and comparative kinetics under tightly managed in vitro conditions.

Historical and Scientific Background

GRF-based peptides, such as MOD GRF 1-29, alongside GHRP-class peptides like Ipamorelin, have emerged as established tools in biological research targeting GH axis modulation. This dual-peptide blend provides investigators with a platform to explore biochemical synergies, signaling frameworks, and receptor dynamics using two validated short-duration agents.

Research Focus on Mechanisms

• Simulation of short-acting GH axis stimulation

• In vitro probing of pituitary receptor engagements

• Biochemical comparison of GRF and GHRP activities

• Cellular response profiling in regulated environments

• Structure-function analysis of GH-modulating peptidesl GH